Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JinFuNing in diabetic wounds
NCT06608303Completed
- Sponsor
- Peking University Third Hospital
- Start
- Oct 2024
- Primary completion
- Mar 2025
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Randomised, single-blind trial of molgramostim in diabetic foot ulcer (DFU) (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Wound area reduction rate at 2 weeks. Started Oct 2024; status: completed.
02
Drugs
molgramostim
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT06608303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06608303.